A new study of nearly 149,000 women with diabetes over 14 years showed an overall 18% reduced breast cancer risk for women who used low-dose aspirin compared to those who did not.
The study design and results are published in an article in Journal of Women’s Health, ein Peer-review-Veröffentlichung von Mary Ann Liebert, Inc., Verlage.
In dem Artikel mit dem Titel “Low-Dose Aspirin Reduces Breast Cancer Risk in Women with Diabetes: A Nationwide Retrospective Cohort Study in Taiwan,” Yi-Sun Yang, MD, PhD, Chien-Ning Huang, MD, PhD, and coauthors from Chung Shan Medical University Hospital and Hung Kuang University, Taichung, Taiwan, defined low-dose aspirin use as intake of 75-165 mg daily.
The researchers reported that a high cumulative dose of aspirin over the 14-year study period reduced breast cancer risk by 47%, whereas low and medium cumulative doses did not reduce risk.
“Frauen mit Typ 2 diabetes have an increased risk of breast cancer, and these results suggest that the same low-dose aspirin that many of these women take to prevent cardiovascular disease may also help reduce their risk of breast cancer,” sagt Susan G. Kornstein, MD, Chefredakteur der Zeitschrift der Frauen ’ s Gesundheit, Executive Director von der Virginia Commonwealth University Institute for Women ’ s Gesundheit, Richmond, VA, und Präsident der Academy of Women ’ s Gesundheit.
Kredit: Mary Ann Liebert, Inc., Verlage